March 31 (UPI) -- Johnson & Johnson said Wednesday a quality control issue at a vaccine manufacturing plant in Maryland has delayed the delivery of millions of vaccine doses.
The vaccine manufacturer issued a statement explaining the quality control process identified one batch of drug substance at Emergent Biosolutions in Maryland "did not meet quality standards" and the doses were therefore never advanced to the filing and finishing stages.